1253 related articles for article (PubMed ID: 11277825)
1. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
Schwartz GG; Olsson AG; Ezekowitz MD; Ganz P; Oliver MF; Waters D; Zeiher A; Chaitman BR; Leslie S; Stern T;
JAMA; 2001 Apr; 285(13):1711-8. PubMed ID: 11277825
[TBL] [Abstract][Full Text] [Related]
2. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
Waters DD; Schwartz GG; Olsson AG; Zeiher A; Oliver MF; Ganz P; Ezekowitz M; Chaitman BR; Leslie SJ; Stern T;
Circulation; 2002 Sep; 106(13):1690-5. PubMed ID: 12270864
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
Schwartz GG; Oliver MF; Ezekowitz MD; Ganz P; Waters D; Kane JP; Texter M; Pressler ML; Black D; Chaitman BR; Olsson AG
Am J Cardiol; 1998 Mar; 81(5):578-81. PubMed ID: 9514453
[TBL] [Abstract][Full Text] [Related]
4. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
Kinlay S; Schwartz GG; Olsson AG; Rifai N; Sasiela WJ; Szarek M; Ganz P; Libby P;
Circulation; 2004 Jul; 110(4):386-91. PubMed ID: 15262833
[TBL] [Abstract][Full Text] [Related]
5. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
Kinlay S; Schwartz GG; Olsson AG; Rifai N; Leslie SJ; Sasiela WJ; Szarek M; Libby P; Ganz P;
Circulation; 2003 Sep; 108(13):1560-6. PubMed ID: 12975259
[TBL] [Abstract][Full Text] [Related]
6. Are early clinical effects of cholesterol lowering mediated through effects on inflammation?
Olsson AG; Schwartz GG; Jonasson L; Linderfalk C
Acta Physiol Scand; 2002 Oct; 176(2):147-50. PubMed ID: 12354174
[TBL] [Abstract][Full Text] [Related]
7. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Szarek M; Tsai J;
JAMA; 2005 Nov; 294(19):2437-45. PubMed ID: 16287954
[TBL] [Abstract][Full Text] [Related]
8. A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.
Gómez-Gerique JA; Casciano R; Stern L; Rejas J
Eur J Health Econ; 2004 Oct; 5(3):278-84. PubMed ID: 15714350
[TBL] [Abstract][Full Text] [Related]
9. Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction.
Correia LC; Spósito AC; Lima JC; Magalhães LP; Passos LC; Rocha MS; D'Oliveira A; Esteves JP
Am J Cardiol; 2003 Aug; 92(3):298-301. PubMed ID: 12888137
[TBL] [Abstract][Full Text] [Related]
10. Lipid-lowering therapy in acute coronary syndromes.
Sacks FM
JAMA; 2001 Apr; 285(13):1758-60. PubMed ID: 11277832
[No Abstract] [Full Text] [Related]
11. Acute statin treatment in reducing risk after acute coronary syndrome: the MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) Trial.
Ahsan CH; Shah A; Ezekowitz M
Curr Opin Cardiol; 2001 Nov; 16(6):390-3. PubMed ID: 11704711
[TBL] [Abstract][Full Text] [Related]
12. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial.
Schwartz GG; Olsson AG; Szarek M; Sasiela WJ
Diabetes Care; 2005 Oct; 28(10):2508-13. PubMed ID: 16186288
[TBL] [Abstract][Full Text] [Related]
13. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
[TBL] [Abstract][Full Text] [Related]
14. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.
Olsson AG; Schwartz GG; Szarek M; Sasiela WJ; Ezekowitz MD; Ganz P; Oliver MF; Waters D; Zeiher A
Eur Heart J; 2005 May; 26(9):890-6. PubMed ID: 15764620
[TBL] [Abstract][Full Text] [Related]
15. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
O'Donoghue M; Morrow DA; Sabatine MS; Murphy SA; McCabe CH; Cannon CP; Braunwald E
Circulation; 2006 Apr; 113(14):1745-52. PubMed ID: 16537575
[TBL] [Abstract][Full Text] [Related]
17. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Cannon CP; Braunwald E; McCabe CH; Rader DJ; Rouleau JL; Belder R; Joyal SV; Hill KA; Pfeffer MA; Skene AM;
N Engl J Med; 2004 Apr; 350(15):1495-504. PubMed ID: 15007110
[TBL] [Abstract][Full Text] [Related]
18. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Schwartz GG; Bessac L; Berdan LG; Bhatt DL; Bittner V; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Mahaffey KW; Moryusef A; Pordy R; Roe MT; Rorick T; Sasiela WJ; Shirodaria C; Szarek M; Tamby JF; Tricoci P; White H; Zeiher A; Steg PG
Am Heart J; 2014 Nov; 168(5):682-9. PubMed ID: 25440796
[TBL] [Abstract][Full Text] [Related]
19. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial.
Zhao SP; Yu BL; Peng DQ; Huo Y
Atherosclerosis; 2014 Apr; 233(2):707-712. PubMed ID: 24603217
[TBL] [Abstract][Full Text] [Related]
20. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Sever PS; Poulter NR; Dahlof B; Wedel H;
J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
